Aprocitentan
Aprocitentan is the medicine in Tryvio, a tablet. The US label calls it an endothelin receptor antagonist. The label lists, as its indication, the treatment of hypertension, to lower blood pressure, in combination with other blood pressure medicines, in adults whose blood pressure is not adequately controlled on other drugs, and says no controlled trials show that it lowers the risk of heart attacks or strokes. A boxed warning says it is contraindicated during pregnancy because it may cause fetal harm; that risk concerns the unborn child and is recorded separately. The atlas holds no trial results for it.
Also called Tryvio
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 2679059; the label UNII MZI81HV01P equals the ingredient's. MeSH has no descriptor for aprocitentan (an exact-label lookup returned an empty list on 2026-11-19). RxClass lists the FDA established pharmacologic class Endothelin Receptor Antagonist, and the label says the same. The atlas class page for endothelin receptor antagonists is not in the corpus yet, so the record files under the medicines front only. The label read is the Idorsia Pharmaceuticals Ltd label for Tryvio, application NDA217686, effective 2026-08-14 in openFDA; it is the only openFDA label returned for the ingredient, and Drugs@FDA lists one application with one product. The adult indication and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records the label indication, the class, the boxed-warning title and one sentence, and the mechanism sentence only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says aprocitentan is an endothelin receptor antagonist that inhibits the binding of endothelin-1 to ET A and ET B receptors.
Claims and evidence
Context Adults with hypertension that is not adequately controlled on other drugs, as described in the US label of Tryvio
- Recipient
- Recipient not specified
- Population
- Adult patients with hypertension who are not adequately controlled on other drugs, taking the medicine in combination with other antihypertensive drugs, as the indications section of the label describes them. The passages read give no other age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Adult patients with hypertension who are not adequately controlled on other drugs, treated in combination with other antihypertensive drugs
- Excluded
- None stated
The US label of Tryvio (aprocitentan tablets; Idorsia Pharmaceuticals Ltd, application NDA217686; the version dated 2026-08-14 in openFDA) calls the product an endothelin receptor antagonist. It lists the treatment of hypertension, to lower blood pressure, in combination with other antihypertensive drugs, in adult patients who are not adequately controlled on other drugs, as the indication. The label also says there are no controlled trials showing that the medicine reduces the risk of fatal and non-fatal cardiovascular events.
Applies to Recipient not specified Adults with hypertension that is not adequately controlled on other drugs, as described in the US label of Tryvio
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The label also gives a boxed warning about the unborn child, recorded in a separate claim and context. Contraindications, other warnings, interactions, the lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-19
- Next evidence check due
- Not scheduled
Sources and citations (6)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA217686.
- Retrieved
- Source effective date
- 2026-08-14
- Source state
- Current
- Version fingerprint
3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260814.
- Retrieved
- Source effective date
- 2026-08-14
- Source state
- Current
- Version fingerprint
3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].description[0], first sentence
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-APR-LB-04).
- Retrieved
- Source effective date
- 2026-08-14
- Source state
- Current
- Version fingerprint
3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], indication statement
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-APR-LB-05).
- Retrieved
- Source effective date
- 2026-08-14
- Source state
- Current
- Version fingerprint
3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], indication statement, population
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-APR-LB-06).
- Retrieved
- Source effective date
- 2026-08-14
- Source state
- Current
- Version fingerprint
3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], outcomes sentence
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-APR-LB-07).
- Retrieved
- Source effective date
- 2026-08-14
- Source state
- Current
- Version fingerprint
3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context The developing fetus, for a person taking aprocitentan during pregnancy, as described in a US label boxed warning
- Recipient
- Fetal
- Population
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Fetus during pregnancy; the passage read gives no gestational ages
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Excluded
- None stated
The same US label of Tryvio carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause fetal harm if used by pregnant patients.
Applies to Fetal The developing fetus, for a person taking aprocitentan during pregnancy, as described in a US label boxed warning
- Certainty method
- Not assessed
- Limitations
- This claim records the boxed-warning title and its first statement only. The warning also tells prescribers what to do before, during and after treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-19
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA217686.
- Retrieved
- Source effective date
- 2026-08-14
- Source state
- Current
- Version fingerprint
3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260814.
- Retrieved
- Source effective date
- 2026-08-14
- Source state
- Current
- Version fingerprint
3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-APR-LB-09).
- Retrieved
- Source effective date
- 2026-08-14
- Source state
- Current
- Version fingerprint
3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], first sentence
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-APR-LB-10).
- Retrieved
- Source effective date
- 2026-08-14
- Source state
- Current
- Version fingerprint
3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In pregnancy 1
The same US label of Tryvio carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause fetal harm if used by pregnant patients.
Applies to Fetal The developing fetus, for a person taking aprocitentan during pregnancy, as described in a US label boxed warning
Population, setting and follow-up
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Fetus during pregnancy; the passage read gives no gestational ages
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records the boxed-warning title and its first statement only. The warning also tells prescribers what to do before, during and after treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-19
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA217686.
- Retrieved
- Source effective date
- 2026-08-14
- Source state
- Current
- Version fingerprint
3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260814.
- Retrieved
- Source effective date
- 2026-08-14
- Source state
- Current
- Version fingerprint
3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-APR-LB-09).
- Retrieved
- Source effective date
- 2026-08-14
- Source state
- Current
- Version fingerprint
3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], first sentence
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-APR-LB-10).
- Retrieved
- Source effective date
- 2026-08-14
- Source state
- Current
- Version fingerprint
3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension, to lower blood pressure, in combination with other antihypertensive drugs in adults not adequately controlled on other drugs, as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified Adults with hypertension that is not adequately controlled on other drugs, as described in the US label of Tryvio
The US label of Tryvio (aprocitentan tablets; Idorsia Pharmaceuticals Ltd, application NDA217686; the version dated 2026-08-14 in openFDA) calls the product an endothelin receptor antagonist. It lists the treatment of hypertension, to lower blood pressure, in combination with other antihypertensive drugs, in adult patients who are not adequately controlled on other drugs, as the indication. The label also says there are no controlled trials showing that the medicine reduces the risk of fatal and non-fatal cardiovascular events.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The label also gives a boxed warning about the unborn child, recorded in a separate claim and context. Contraindications, other warnings, interactions, the lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:aprocitentan- Content hash
c495249777c7144244fa3a16ceee735712d1722cd0ba89328df67117a3159e10